Trenaxa 500 - Trenaxa 500 is a man-made form of an amino acid (protein) called lysine. Trenaxa 500 prevents enzymes in the body from breaking down blood clots.
The Cyklokapron and Lysteda brands of Trenaxa 500 are used for different medical conditions.
Cyklokapron is used to prevent bleeding in people with hemophilia who need to have a tooth pulled. This medication is usually given just before the dental procedure, and daily for up to 8 days afterward.
Lysteda is used to treat heavy menstrual bleeding. This medication will not treat premenstrual syndrome (PMS).
Trenaxa 500 may also be used for purposes not listed in this medication guide.
Pharmacology: Inhibits fibrinolysis to stop bleeding.
Indication: For short-term use in patients with hemophilia to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction (injection only); treatment of cyclic heavy menstrual bleeding (oral only).
Unlabeled Uses
Treatment of GI hemorrhage, hereditary angioneurotic edema, primary or intrauterine device–induced menorrhagia, or recurrent epistaxis; prevention of perioperative bleeding or rebleeding after subarachnoid hemorrhage.
Trenaxa 500 is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Trenaxa 500 is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Trenaxa 500 is about 10 times more potent in vitro than aminocaproic acid. Trenaxa 500 binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Trenaxa 500 in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by Trenaxa 500 may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1).
Oral Short-term management of haemorrhage
Adult: 1-1.5 g or 15-25 mg/kg 2-4 times daily.
Child: 25 mg/kg bid or tid. Renal impairment: Adjust dose based on serum creatinine concentration: 120-250 micromol/l: 15 mg/kg bid daily; 250-500 micromol/l: 15 mg/kg once daily; >500 micromol/l: 7.5 mg/kg once daily or 15 mg/kg once every 48 hr. Oral Management of hereditary angioedema
Adult: 1-1.5 g bid or tid.
Child: 25 mg/kg bid or tid. Renal impairment: Adjust dose based on serum creatinine concentration: 120-250 micromol/l: 15 mg/kg bid daily; 250-500 micromol/l: 15 mg/kg once daily; >500 micromol/l: 7.5 mg/kg once daily or 15 mg/kg once every 48 hr. Intravenous Short-term management of haemorrhage
Adult: 0.5-1 g or 10 mg/kg tid or 25-50 mg/kg daily by continuous infusion.
Child: 10 mg/kg bid or tid. Renal impairment: Adjust dose based on the serum-creatinine concentration: 120-250 micromol/l: 10 mg/kg bid daily; 250-500 micromoles/l: 10 mg/kg once daily; >500 micromol/l: 5 mg/kg once daily or 10 mg/kg once every 48 hr. Incompatibility: Incompatible with benzylpenicillin.
Trenaxa 500 helps to prevent and reduce bleeding. It is used to control bleeding after certain surgical procedures, especially in people whose blood cannot clot properly or takes a longer time to clot. It may also be used to control bleeding in other situations, as decided by your doctor.
Indications:
Adult: PO Short-term management of haemorrhage 1-1.5 g 2-4 times/day. Long-term management of hereditary angioedema 1-1.5 g 2-3 times/day. IV Short-term management of haemorrhage 0.5-1 g 3 times/day.
Oral Short-term management of haemorrhage
Adult: 1-1.5 g or 15-25 mg/kg 2-4 times daily.
Child: 25 mg/kg bid or tid. Renal impairment: Adjust dose based on serum creatinine concentration: 120-250 micromol/l: 15 mg/kg bid daily; 250-500 micromol/l: 15 mg/kg once daily; >500 micromol/l: 7.5 mg/kg once daily or 15 mg/kg once every 48 hr. Oral Management of hereditary angioedema
Adult: 1-1.5 g bid or tid.
Child: 25 mg/kg bid or tid. Renal impairment: Adjust dose based on serum creatinine concentration: 120-250 micromol/l: 15 mg/kg bid daily; 250-500 micromol/l: 15 mg/kg once daily; >500 micromol/l: 7.5 mg/kg once daily or 15 mg/kg once every 48 hr. Intravenous Short-term management of haemorrhage
Adult: 0.5-1 g or 10 mg/kg tid or 25-50 mg/kg daily by continuous infusion.
Child: 10 mg/kg bid or tid. Renal impairment: Adjust dose based on the serum-creatinine concentration: 120-250 micromol/l: 10 mg/kg bid daily; 250-500 micromoles/l: 10 mg/kg once daily; >500 micromol/l: 5 mg/kg once daily or 10 mg/kg once every 48 hr. Special Populations: Renal impairment: Short-term management of haemorrhage: CrCl: >500 micromol/L: 12.5 mg/kg body wt once daily oral dose or 5 mg/kg IV once daily; 250-500 micromol/L: 25 mg/kg body wt bid oral dose or 10 mg IV once daily; 120-250 micromol/L: 25 mg/kg bid oral dose or 10 mg/kg body wt IV bid. Incompatibility: Incompatible with benzylpenicillin.
General and local bleeding or bleeding diseases. |
brands or generic drugs
